Palbociclib and Posaconazole: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A inhibition may increase anticancer-drug exposure and toxicity.
Clinical significance and safety
Palbociclib with Posaconazole can increase exposure to the affected anticancer medicine and raise the risk of serious adverse effects. Strong CYP3A inhibitors should be avoided where possible. If the combination is necessary, the oncology team must plan the medicine-specific interruption or dose modification and close toxicity monitoring. Do not change the doses yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.